Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2010)
A trial looking at MFEz T cells, chemotherapy and IL-2 (interleukin 2) for cancers that test positive for carcinoembryonic antigen (CEA) (PH1/105)
D. Ryan, T. Hong, N. Bardeesy (2014)
Pancreatic adenocarcinoma.The New England journal of medicine, 371 22
A. Posey, R. Schwab, A. Boesteanu, Catharina Steentoft, U. Mandel, B. Engels, J. Stone, Thomas Madsen, K. Schreiber, K. Haines, Alexandria Cogdill, Taylor J. Chen, Decheng Song, J. Scholler, D. Kranz, M. Feldman, R. Young, B. Keith, H. Schreiber, H. Clausen, L. Johnson, C. June (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.Immunity, 44 6
S. Riddell, D. Sommermeyer, C. Berger, Lingfeng Liu, Ashwini Balakrishnan, A. Salter, M. Hudecek, D. Maloney, C. Turtle (2014)
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.Cancer journal, 20 2
R. Morgan, J. Yang, M. Kitano, M. Dudley, C. Laurencot, S. Rosenberg (2010)
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Molecular therapy : the journal of the American Society of Gene Therapy, 18 4
S. Hammarström (1999)
The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.Seminars in cancer biology, 9 2
M. Campoli, S. Ferrone (2008)
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceOncogene, 27
Linda Sandin, F. Eriksson, P. Ellmark, A. Loskog, T. Tötterman, S. Mangsbo (2014)
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivoOncoimmunology, 3
Agnes Witkiewicz, T. Williams, J. Cozzitorto, Brandice Durkan, S. Showalter, C. Yeo, J. Brody (2008)
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.Journal of the American College of Surgeons, 206 5
D. Basso, P. Fogar, M. Falconi, Elisa Fadi, C. Sperti, C. Frasson, E. Greco, D. Tamburrino, Sara Teolato, Stefania Moz, Dania Bozzato, M. Pelloso, A. Padoan, G. Franchis, E. Gnatta, M. Facco, C. Zambon, F. Navaglia, C. Pasquali, G. Basso, G. Semenzato, S. Pedrazzoli, P. Pederzoli, M. Plebani (2013)
Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro StudyPLoS ONE, 8
M. Serafini, M. Manganini, G. Borleri, M. Bonamino, L. Imberti, A. Biondi, J. Golay, A. Rambaldi, M. Introna (2004)
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease.Human gene therapy, 15 1
C. Bonini, G. Ferrari, S. Verzeletti, P. Servida, E. Zappone, L. Ruggieri, M. Ponzoni, S. Rossini, F. Mavilio, C. Traversari, C. Bordignon (1997)
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.Science, 276 5319
E. Velde, A. Franke, R. Hillegersberg, Sabrina Elshof, R. Weger, I. Rinkes, P. Diest (2009)
HER-family gene amplification and expression in resected pancreatic cancer.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 35 10
Y. Hao, Raju Reddy, Sae-Hong Lee, Jami Milam, Chung Owyang, M. DiMagno (2005)
DEPLETION OF HEAT SHOCK PROTEIN-70 (HSP70) CAUSES APOPTOSIS IN PANCREATIC CANCER CELLSPancreas, 31
H. Safran, M. Steinhoff, S. Mangray, R. Rathore, T. King, L. Chai, Katya Berzein, T. Moore, D. Iannitti, P. Reiss, T. Pasquariello, P. Akerman, D. Quirk, R. Mass, L. Goldstein, U. Tantravahi (2001)
Overexpression of the HER-2/ neu Oncogene in Pancreatic AdenocarcinomaAmerican Journal of Clinical Oncology, 24
R. Nomura, H. Fujii, M. Abe, H. Sugo, Y. Ishizaki, S. Kawasaki, O. Hino (2013)
Mesothelin expression is a prognostic factor in cholangiocellular carcinoma.International surgery, 98 2
Wolfram Bernstorff, R. Spanjaard, Allen Chan, D. Lockhart, Noriaki Sadanaga, Isabelle Wood, Matthias Peiper, P. Goedegebuure, T. Eberlein (1999)
Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.Surgery, 125 1
D. Thomis, S. Marktel, C. Bonini, C. Traversari, Michael Gilman, C. Bordignon, Tim Clackson (2001)
A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease.Blood, 97 5
E. Moon, C. Carpenito, Jing Sun, Liang-Chuan Wang, V. Kapoor, J. Predina, D. Powell, J. Riley, C. June, S. Albelda (2011)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody ReceptorClinical Cancer Research, 17
Carla Kim, E. Jackson, Amber Woolfenden, Sharon Lawrence, I. Babar, Sinae Vogel, D. Crowley, R. Bronson, T. Jacks (2005)
Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung CancerCell, 121
C. O’Brien, A. Pollett, S. Gallinger, J. Dick (2007)
A human colon cancer cell capable of initiating tumour growth in immunodeficient miceNature, 445
M. Yasukawa, H. Ohminami, J. Arai, Y. Kasahara, Y. Ishida, S. Fujita (2000)
Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans.Blood, 95 7
S. Grupp, M. Kalos, D. Barrett, R. Aplenc, David Porter, S. Rheingold, D. Teachey, A. Chew, B. Hauck, J. Wright, Michael Milone, Bruce Levine, Carl June (2013)
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.The New England journal of medicine, 368 16
Amit Maliar, Charlotte Servais, T. Waks, M. Chmielewski, R. Lavy, P. Altevogt, H. Abken, Z. Eshhar (2012)
Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.Gastroenterology, 143 5
R. Vatner, B. Cooper, C. Vanpouille-Box, S. Demaria, S. Formenti (2014)
Combinations of Immunotherapy and Radiation in Cancer TherapyFrontiers in Oncology, 4
J. Chang, Yong-jian Jiang, V. Pillarisetty (2016)
Role of immune cells in pancreatic cancer from bench to clinical applicationMedicine, 95
R. Hassan, W. Ebel, E. Routhier, Rina Patel, J. Kline, Jingli Zhang, Qimin Chao, S. Jacob, H. Turchin, L. Gibbs, M. Phillips, Shiyama Mudali, C. Iacobuzio-Donahue, E. Jaffee, M. Moreno, I. Pastan, P. Sass, N. Nicolaides, L. Grasso (2007)
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.Cancer immunity, 7
A. Hombach, H. Köhler, G. Rappl, H. Abken (2006)
Human CD4+ T Cells Lyse Target Cells via Granzyme/Perforin upon Circumvention of MHC Class II Restriction by an Antibody-Like Immunoreceptor1The Journal of Immunology, 177
H. Pegram, Jae Park, R. Brentjens (2014)
CD28z CARs and Armored CARsThe Cancer Journal, 20
W. Allum, H. Stokes, F. Macdonald, J. Fielding (1986)
Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry.Journal of Clinical Pathology, 39
M. Davila, I. Rivière, Xiuyan Wang, S. Bartido, Jae Park, K. Curran, S. Chung, J. Stefanski, Oriana Bórquez-Ojeda, M. Olszewska, Jinrong Qu, Teresa Wasielewska, Q. He, Mitsú Fink, Himaly Shinglot, M. Youssif, M. Satter, Yongzeng Wang, James Hosey, Hilda Quintanilla, E. Halton, Y. Bernal, Diana Bouhassira, M. Arcila, M. Gonen, G. Roboz, P. Maslak, D. Douer, M. Frattini, S. Giralt, M. Sadelain, R. Brentjens (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 6
G. Bellone, A. Turletti, E. Artusio, Katia Mareschi, A. Carbone, D. Tibaudi, A. Robecchi, G. Emanuelli, U. Rodeck (1999)
Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients.The American journal of pathology, 155 2
M. Sadelain, R. Brentjens, I. Rivière (2013)
The basic principles of chimeric antigen receptor design.Cancer discovery, 3 4
C. Qu, C. Qu, Yong Li, Yan Song, Yan Song, S. Rizvi, C. Raja, David Zhang, J. Samra, J. Samra, Ross Smith, Ross Smith, A. Perkins, C. Apostolidis, B. Allen, B. Allen (2004)
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugateBritish Journal of Cancer, 91
G. Beatty, A. Haas, M. Maus, D. Torigian, M. Soulen, G. Plesa, A. Chew, Yangbing Zhao, B. Levine, S. Albelda, M. Kalos, C. June (2013)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid MalignanciesCancer Immunology Research, 2
P. Yurchenco, J. Schittny (1990)
Molecular architecture of basement membranesThe FASEB Journal, 4
A. Stasi, B. Angelis, C. Rooney, L. Zhang, Aruna Mahendravada, A. Foster, H. Heslop, M. Brenner, G. Dotti, B. Savoldo (2009)
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.Blood, 113 25
Daniel Lee, J. Kochenderfer, M. Stetler-Stevenson, Yongzhi Cui, Cindy Delbrook, S. Feldman, T. Fry, R. Orentas, M. Sabatino, N. Shah, S. Steinberg, D. Stroncek, Nicholas Tschernia, C. Yuan, Hua Zhang, Ling Zhang, S. Rosenberg, A. Wayne, C. Mackall (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 385
B. Giles, Banga Neal, M. HammondToby, J. ImberCharles, 常敏, 鲁重美 (2012)
Only women with symptoms need to have their breast implants removed, says governmentBMJ, 15
P. Szotek, R. Pieretti-Vanmarcke, P. Masiakos, D. Dinulescu, D. Connolly, R. Foster, D. Dombkowski, F. Preffer, D. Maclaughlin, P. Donahoe (2006)
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.Proceedings of the National Academy of Sciences of the United States of America, 103 30
JH Chang, Y Jiang, VG Pillarisetty (2016)
Role of immune cells in pancreatic cancer from bench to clinical application: an updated reviewMedicine, 95
J. Craddock, An Lu, A. Bear, M. Pule, M. Brenner, C. Rooney, A. Foster (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2bJournal of Immunotherapy, 33
C. Feig, A. Gopinathan, A. Neesse, Derek Chan, N. Cook, D. Tuveson (2012)
The Pancreas Cancer MicroenvironmentClinical Cancer Research, 18
E. Pichinuk, I. Benhar, O. Jacobi, Michael Chalik, Lotem Weiss, R. Ziv, C. Sympson, A. Karwa, N. Smorodinsky, D. Rubinstein, D. Wreschner (2012)
Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells.Cancer research, 72 13
G. Albers, G. Fleuren, M. Escribano, M. Nap (1988)
Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma.American journal of clinical pathology, 90 1
Carolyn Clark, S. Hingorani, R. Mick, C. Combs, D. Tuveson, R. Vonderheide (2007)
Dynamics of the immune reaction to pancreatic cancer from inception to invasion.Cancer research, 67 19
Amy Chen, Andrew Chen (2020)
Fluorescence In Situ HybridizationDefinitions
Daniel Lee, R. Gardner, D. Porter, C. Louis, N. Ahmed, M. Jensen, S. Grupp, C. Mackall (2014)
Current concepts in the diagnosis and management of cytokine release syndrome.Blood, 124 2
L. Ries, D. Harkins, Martin Krapcho, A. Mariotto, B. Miller, E. Feuer, L. Clegg, M. Eisner, Marie-Josèphe Horner, N. Howlader, Matthew Hayat, B. Hankey, B. Edwards (2006)
SEER Cancer Statistics Review, 1975-2003
Y. Li, Rena Xian, A. Ziober, J. Conejo-Garcia, A. Perales-Puchalt, C. June, Paul Zhang, J. Tchou (2014)
Mesothelin expression is associated with poor outcomes in breast cancerBreast Cancer Research and Treatment, 147
Daniel Nummer, E. Suri‐Payer, H. Schmitz‐Winnenthal, A. Bonertz, Luis Galindo, Dalibor Antolovich, M. Koch, M. Büchler, J. Weitz, V. Schirrmacher, P. Beckhove (2007)
Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma.Journal of the National Cancer Institute, 99 15
(2010)
A CRUK phase I trial of adoptive transfer of autologous tumour antigen-specific T cells with pre-conditioning chemotherapy and intravenous IL2 in patients with advanced CEA positive tumours
C Li, DG Heidt, P Dalerba (2007)
Identification of pancreatic cancer stem cellsCan Res, 67
Zeguo Zhao, M. Condomines, Sjoukje Stegen, F. Perna, Christopher Kloss, Gertrude Gunset, J. Plotkin, M. Sadelain (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.Cancer cell, 28 4
Kai Chang, I. Pastan (1996)
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proceedings of the National Academy of Sciences of the United States of America, 93 1
Sandra Gendler (2001)
MUC1, The Renaissance MoleculeJournal of Mammary Gland Biology and Neoplasia, 6
J. Winter, Laura Tang, D. Klimstra, M. Brennan, J. Brody, F. Rocha, X. Jia, L. Qin, M. D'Angelica, R. DeMatteo, Y. Fong, W. Jarnagin, E. O’Reilly, P. Allen (2012)
A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as BiomarkersPLoS ONE, 7
V Vaccaro, I Sperduti, M Milella (2011)
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med, 365
I. Rajagopal, S. Niveditha, R. Sahadev, P. Nagappa, S. Rajendra (2015)
HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas.Journal of clinical and diagnostic research : JCDR, 9 3
A. Shimizu, S. Hirono, M. Tani, M. Kawai, K. Okada, M. Miyazawa, Y. Kitahata, Yasushi Nakamura, T. Noda, S. Yokoyama, H. Yamaue (2012)
Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinomaCancer Science, 103
Stephanie Bunt, Ashley Mohr, Jennifer Bailey, P. Grandgenett, M. Hollingsworth (2013)
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancerCancer Immunology, Immunotherapy, 62
Xiao-yan Zhao, B. Subramanyam, N. Sarapa, S. Golfier, H. Dinter (2016)
Novel Antibody Therapeutics Targeting Mesothelin In Solid TumorsClinical Cancer Drugs, 3
R. Panni, Dominic Sanford, B. Belt, Jonathan Mitchem, Lori Worley, Brian Goetz, P. Mukherjee, A. Wang-Gillam, Daniel Link, D. DeNardo, S. Goedegebuure, D. Linehan (2014)
Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancerCancer Immunology, Immunotherapy, 63
F. Kawamata, H. Kamachi, T. Einama, S. Homma, M. Tahara, M. Miyazaki, S. Tanaka, T. Kamiyama, H. Nishihara, A. Taketomi, S. Todo (2012)
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer.International journal of oncology, 41 6
A. Bittoni, A. Mandolesi, K. Andrikou, M. Santoni, S. Alfonsi, A. Lanese, C. Loretelli, C. Pellei, F. Piva, M. Scarpelli, S. Cascinu (2015)
HER family Receptor Expression and Prognosis in Pancreatic CancerThe International Journal of Biological Markers, 30
D. Le, A. Wang-Gillam, V. Picozzi, T. Greten, T. Crocenzi, G. Springett, M. Morse, H. Zeh, D. Cohen, R. Fine, Beth Onners, J. Uram, D. Laheru, Eric Lutz, S. Solt, A. Murphy, J. Skoble, E. Lemmens, J. Grous, Thomas Dubensky, D. Brockstedt, E. Jaffee (2015)
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 12
M. Chmielewski, O. Hahn, G. Rappl, Michael Nowak, I. Schmidt-Wolf, A. Hombach, H. Abken (2012)
T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice.Gastroenterology, 143 4
K. Yamaguchi, M. Enjoji, M. Tsuneyoshi (1991)
Pancreatoduodenal carcinoma: A clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19‐9Journal of Surgical Oncology, 47
K. Curran, H. Pegram, R. Brentjens (2012)
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directionsThe Journal of Gene Medicine, 14
A. Bazhin, I. Shevchenko, V. Umansky, J. Werner, S. Karakhanova (2013)
Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapyCancer Immunology, Immunotherapy, 63
E. Kolyvas, Michael Rudloff, M. Poruchynsky, Rebekah Landsman, K. Hollevoet, D. Venzon, C. Alewine (2016)
Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanesOncotarget, 8
(2013)
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
S. Eikawa, Mikako Nishida, Shusaku Mizukami, C. Yamazaki, E. Nakayama, H. Udono (2015)
Immune-mediated antitumor effect by type 2 diabetes drug, metforminProceedings of the National Academy of Sciences, 112
A. Collins, P. Berry, Catherine Hyde, M. Stower, N. Maitland (2005)
Prospective identification of tumorigenic prostate cancer stem cells.Cancer research, 65 23
Liza John, Christel Devaud, Connie Duong, C. Yong, P. Beavis, N. Haynes, Melvyn Chow, M. Smyth, M. Kershaw, P. Darcy (2013)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T CellsClinical Cancer Research, 19
A Thomas, Y Chen, SM Steinberg (2015)
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosisOncotarget, 6
J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. Parkin, D. Forman, F. Bray (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 136
W. Cheng, C. Huang, M.-C. Chang, Y-H Hu, Y. Chiang, Y-L Chen, C. Hsieh, C.-A. Chen (2009)
High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaBritish Journal of Cancer, 100
Ignazio Caruana, B. Savoldo, V. Hoyos, G. Weber, Hao Liu, Eugene Kim, M. Ittmann, D. Marchetti, G. Dotti (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytesNature medicine, 21
M. Chmielewski, A. Hombach, H. Abken (2013)
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T CellsFrontiers in Immunology, 4
K. Behrns (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerYearbook of Surgery, 2012
P. Hermann, Stephan Huber, T. Herrler, A. Aicher, J. Ellwart, M. Guba, C. Bruns, C. Heeschen (2007)
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.Cell stem cell, 1 3
D. Yadav, A. Lowenfels (2013)
The epidemiology of pancreatitis and pancreatic cancer.Gastroenterology, 144 6
M. Komoto, B. Nakata, R. Amano, N. Yamada, M. Yashiro, M. Ohira, K. Wakasa, K. Hirakawa (2009)
HER2 overexpression correlates with survival after curative resection of pancreatic cancerCancer Science, 100
T. Moo-Young, J. Larson, B. Belt, M. Tan, W. Hawkins, T. Eberlein, P. Goedegebuure, D. Linehan (2009)
Tumor-derived TGF-β Mediates Conversion of CD4+Foxp3+ Regulatory T Cells in a Murine Model of Pancreas CancerJournal of Immunotherapy, 32
Chien-Chung Chang, M. Campoli, S. Ferrone (2005)
Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.Advances in cancer research, 93
J. Francisco, C. Cerveny, Damon Meyer, B. Mixan, K. Klussman, D. Chace, Starr Rejniak, K. Gordon, R. DeBlanc, B. Toki, C. Law, S. Doronina, C. Siegall, P. Senter, A. Wahl (2003)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.Blood, 102 4
M. Kershaw, J. Westwood, C. Slaney, P. Darcy (2014)
Clinical application of genetically modified T cells in cancer therapyClinical & Translational Immunology, 3
C. Uyttenhove, L. Pilotte, I. Theate, V. Stroobant, D. Colau, Nicolas Parmentier, T. Boon, B. Eynde (2003)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNature Medicine, 9
S. Kachala, A. Bograd, J. Villena-Vargas, Kei Suzuki, E. Servais, K. Kadota, J. Chou, C. Sima, E. Vertes, V. Rusch, W. Travis, M. Sadelain, P. Adusumilli (2013)
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung AdenocarcinomaClinical Cancer Research, 20
E. Ryschich, Tanja Nötzel, U. Hinz, F. Autschbach, J. Ferguson, Ioan Șimon, J. Weitz, B. Fröhlich, E. Klar, M. Büchler, Jan Schmidt (2005)
Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 11 2 Pt 1
Christina Victor, A. Rech, A. Maity, Ramesh Rengan, Ramesh Rengan, Kristen Pauken, Erietta Stelekati, Joseph Benci, Bihui Xu, Hannah Dada, P. Odorizzi, R. Herati, Kathleen Mansfield, D. Patsch, R. Amaravadi, L. Schuchter, H. Ishwaran, R. Mick, D. Pryma, Xiaowei Xu, M. Feldman, T. Gangadhar, S. Hahn, E. Wherry, R. Vonderheide, A. Minn (2015)
Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in CancerNature, 520
Chimeric antigen receptor (CAR) T cell therapy is genetically engineered tumor antigen-specific anticancer immunotherapy, which after showing great success in hematological malignancies is currently being tried in advanced solid tumors like pancreatic cancer. Immunosuppressive tumor microenvironment and dense fibrous stroma are some of the limitation in the success of this novel therapy. However, genetic modifications and combination therapy is the topic of the research to improve its efficacy. In this article, we summarize the current state of knowledge, limitations, and future prospects for CAR T cell therapy in pancreatic cancer.
Medical Oncology – Springer Journals
Published: May 4, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.